5GH Stock Overview
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Guardant Health, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15.80 |
52 Week High | US$36.60 |
52 Week Low | US$15.80 |
Beta | 0.87 |
1 Month Change | -11.24% |
3 Month Change | -35.77% |
1 Year Change | -29.48% |
3 Year Change | -86.14% |
5 Year Change | n/a |
Change since IPO | -83.28% |
Recent News & Updates
Recent updates
Shareholder Returns
5GH | DE Healthcare | DE Market | |
---|---|---|---|
7D | -2.5% | -1.8% | 1.6% |
1Y | -29.5% | -2.3% | 6.4% |
Return vs Industry: 5GH underperformed the German Healthcare industry which returned -2% over the past year.
Return vs Market: 5GH underperformed the German Market which returned 6.4% over the past year.
Price Volatility
5GH volatility | |
---|---|
5GH Average Weekly Movement | 7.9% |
Healthcare Industry Average Movement | 5.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5GH's share price has been volatile over the past 3 months.
Volatility Over Time: 5GH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 1,774 | Helmy Eltoukhy | https://guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
Guardant Health, Inc. Fundamentals Summary
5GH fundamental statistics | |
---|---|
Market cap | €1.94b |
Earnings (TTM) | -€442.34m |
Revenue (TTM) | €520.30m |
3.7x
P/S Ratio-4.3x
P/E RatioIs 5GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
5GH income statement (TTM) | |
---|---|
Revenue | US$563.95m |
Cost of Revenue | US$227.05m |
Gross Profit | US$336.90m |
Other Expenses | US$816.35m |
Earnings | -US$479.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.94 |
Gross Margin | 59.74% |
Net Profit Margin | -85.02% |
Debt/Equity Ratio | 718.4% |
How did 5GH perform over the long term?
See historical performance and comparison